MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Gossamer Bio Accounts Payables 2011-2025 | GOSS
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Gossamer Bio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.53 M | 1.46 M | 3.24 M | 7.51 M | 956 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.51 M | 956 K | 3.74 M |
Quarterly Accounts Payables Gossamer Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.12 M | 1.88 M | 3.39 M | 2.32 M | 3.06 M | 1 M | 2.66 M | 5.53 M | 1.25 M | 2.2 M | 2.73 M | 1.46 M | 363 K | 3.91 M | 592 K | 3.24 M | 1.18 M | 895 K | 1.07 M | 7.51 M | 7.51 M | 7.51 M | 7.51 M | 956 K | 956 K | 956 K | 956 K | 2.18 M | 2.18 M | 2.18 M | 2.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.51 M | 363 K | 2.66 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
3.22 M | $ 4.75 | -0.94 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
4.69 M | $ 3.03 | -0.49 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
3.24 M | $ 1.17 | - | $ 6.38 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.2 | -5.51 % | $ 1.77 M | USA |
 |
Athersys
ATHX
|
9.16 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
155 K | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 0.22 | 25.2 % | $ 479 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
8.11 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 26.9 | 0.34 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
405 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
9.86 M | $ 9.52 | 0.42 % | $ 140 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
10.1 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
18.5 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
13.3 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
3.65 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
72 M | $ 585.83 | -0.9 % | $ 44.4 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.5 | -1.17 % | $ 15.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
355 K | $ 12.47 | 0.81 % | $ 821 M | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
3.26 M | $ 26.24 | -2.2 % | $ 1.69 M | USA |
 |
Cellectar Biosciences
CLRB
|
5.62 M | $ 2.56 | -7.25 % | $ 31.3 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
51.7 M | $ 10.82 | 0.14 % | $ 700 M | USA |
 |
Biogen
BIIB
|
424 M | $ 175.8 | -0.3 % | $ 25.6 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
11.9 M | - | - | $ 7.29 B | USA |